companydata.dkcompanydata.dk

Afyx Therapeutics A/S: Financial statements 2023

CVR: 38793594

Source: annual report 2023, Danish Business Authority

01/01/2023 – 31/12/2023

Afyx Therapeutics A/S (CVR 38793594) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 6,404,980 and a net result of DKK -2,253,249 compared with DKK -7,273,933 the year before. Equity in the 2023 report amounted to DKK 4,741,118. The solvency ratio was 30%. The company had 5 employees in the financial year.

Gross Profit
DKK 6,404,980
Profit/Loss
DKK -2,253,249
Equity
DKK 4,741,118
Total Assets
DKK 15,826,238
Employees
5

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2023-6.4M-2.3M4.7M5
2022--3.2M-7.3M-1M3
2021-1.5M-814K6.2M2
2020--586K-1.5M4.7M2
2019--1.1M-1.6M1M1

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2023

Afyx Therapeutics A/S appoints new auditorDec 21, 2023

As of December 21, 2023, GILFELT REVISION REGISTRERET REVISIONSANPARTSSELSKAB has been appointed auditor of Afyx Therapeutics A/S.

Ole Baadsgaard joins the board of Afyx Therapeutics A/SDec 21, 2023

As of December 21, 2023, Ole Baadsgaard has joined the board of directors of Afyx Therapeutics A/S.

Claus Juan Møller-San Pedro joins the board of Afyx Therapeutics A/SDec 21, 2023

As of December 21, 2023, Claus Juan Møller-San Pedro has joined the board of directors of Afyx Therapeutics A/S.

Pia Leah Møller-San Pedro joins the board of Afyx Therapeutics A/SDec 21, 2023

As of December 21, 2023, Pia Leah Møller-San Pedro has joined the board of directors of Afyx Therapeutics A/S.

Inphena ApS changes name to Inphena A/SDec 21, 2023

On December 21, 2023, the company changed its name from Inphena ApS to Inphena A/S.

Claus Juan Møller-San Pedro leaves the board of Afyx Therapeutics A/SDec 20, 2023

As of December 20, 2023, Claus Juan Møller-San Pedro has left the board of directors of Afyx Therapeutics A/S.

Søren Anker Nielsen leaves the board of Afyx Therapeutics A/SSep 7, 2023

As of September 7, 2023, Søren Anker Nielsen has left the board of directors of Afyx Therapeutics A/S.

Claus Juan Møller-San Pedro joins Afyx Therapeutics A/S as adm. dir.Sep 7, 2023

As of September 7, 2023, Claus Juan Møller-San Pedro is registered as adm. dir. of Afyx Therapeutics A/S.

Søren Anker Nielsen steps down as adm. dir. of Afyx Therapeutics A/SSep 7, 2023

As of September 7, 2023, Søren Anker Nielsen has stepped down as adm. dir. of Afyx Therapeutics A/S.

Afyx Therapeutics A/S: The 2022 annual report is outMay 22, 2023

Afyx Therapeutics A/S has published its annual report for 2022. Gross profit came to DKK -3,222,038, and the net result was DKK -7,273,933.

About Afyx Therapeutics A/S

Afyx Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2017. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Inphena A/S and Inphena ApS. The management consists of Claus Juan Møller-San Pedro. The board consists of Ole Baadsgaard (chair), Claus Juan Møller-San Pedro, Pia Leah Møller-San Pedro and Søren Mohrsen Kjær. The company is owned by Afyx Capital ApS. The company has 11 employees (2026). In 2025, the company reported a gross profit of DKK 23,138,320 and a net result of DKK 1,518,132 compared with DKK -3,810,585 the year before. Equity in the 2025 report amounted to DKK 36,178,254.

Source: annual report 2025, Danish Business Authority

Other financial years